Euronext NV

Q1: On volatility steroids

15/05/25 -"Euronext delivered a strong Q1, with revenue and pre-tax profit exceeding expectations, driven by elevated market volatility and robust trading activity. Around 80% of growth came from FICC, ..."

PDF page sample
Pages
53
Language
English
Published on
15/05/25
Download
You may also be interested by these reports :
15/05/25
Euronext delivered a strong Q1, with revenue and pre-tax profit exceeding expectations, driven by elevated market volatility and robust trading ...
15/05/25
Eurazeo opened 2025 with strong momentum across its core pillars: fundraising surged, AUM grew, and asset rotation picked up pace. The sharp rebound ...
15/05/25
Return to profit in a tough environment, CHF 18.5mn net result
14/05/25
Porsche SE remains weighed down by the underperformance of both Volkswagen and Porsche AG, delivering yet another underwhelming set of results for ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO